Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
10 stocks we like better than Xeris Biopharma › A competitor's setback was Xeris Biopharma 's (NASDAQ: XERS) gain on Hump Day. On news that a potential commercial threat to one of its three commercialized drugs had been neutralized (at least for now), investors piled into Xeris stock, sending it to a more than 7% price gain. A bullish analyst note reinforced this positive sentiment. That would-be rival is Xeris's fellow biotech Corcept Therapeutics . Wednesday morning, the company announced that the U.S. Food and Drug Administration (FDA) had not approved its relacorilant, a medication used to treat hypertension (high blood pressure) associated with the hormonal disorder hypercortisolism, also known as Cushing's syndrome. In the FDA's complete response letter , Corcept stated in a press release that the regulator cited the lack of additional evidence of the drug's effectiveness as a key reason behind its decision. Corcept has vowed to continue attempting to get the treatment ap
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]Yahoo! Finance
- Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]Yahoo! Finance
- Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]Yahoo! Finance
XERS
Earnings
- 11/6/25 - Miss
XERS
Sec Filings
- 1/9/26 - Form 4
- 1/8/26 - Form 144
- 1/8/26 - Form 8-K
- XERS's page on the SEC website